Share on StockTwits

Verona Pharma Plc (LON:VRP) was downgraded by analysts at Beaufort Securities to a “sell” rating in a research report issued to clients and investors on Tuesday.

Verona Pharma Plc (LON:VRP) traded down 15.00% on Tuesday, hitting GBX 1.19. The stock had a trading volume of 5,026,306 shares. Verona Pharma Plc has a 1-year low of GBX 1.612 and a 1-year high of GBX 2.74. The stock has a 50-day moving average of GBX 2.09 and a 200-day moving average of GBX 2.94.

A number of other firms have also recently commented on VRP. Analysts at WH Ireland reiterated a “buy” rating on shares of Verona Pharma Plc in a research note on Monday. Separately, analysts at N+1 Singer reiterated a “buy” rating on shares of Verona Pharma Plc in a research note on Monday. They now have a GBX 3.50 ($0.06) price target on the stock. Finally, analysts at N+1 Singer reiterated a “buy” rating on shares of Verona Pharma Plc in a research note on Monday, April 28th. They now have a GBX 3.50 ($0.06) price target on the stock.

Verona Pharma plc is a biotechnology company. The Company is engaged in research, discovery and development of drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (LON:VRP), asthma, allergic rhinitis (hay fever), and cough.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.